drugset
drugset / Trial / NCT05324124

A Study of the Effect of Food on Selpercatinib (LY3527723) in Healthy Participants

NCT05324124 ↗

Phase 1 Completed 46 enrolled Loxo Oncology, Inc. Eli Lilly and Company · collab
RandomizedCrossoverOpen-labelBasic science

Summary

The main purpose of this study is to learn about how food affects selpercatinib in healthy participants. The selpercatinib will be administered in fed and fasted states. Participation could last about 7 weeks.

Timeline

Start
2022-04-19
Primary completion
2022-06-22
Completion
2022-06-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Selpercatinib Small molecule 160 mg Oral

Indications

No indication recorded.